Author: Beigel, John H.; Tebas, Pablo; Elie-Turenne, Marie-Carmelle; Bajwa, Ednan; Bell, Todd E.; Cairns, Charles B.; Shoham, Shmuel; Deville, Jaime G.; Feucht, Eric; Feinberg, Judith; Luke, Thomas; Raviprakash, Kanakatte; Danko, Janine; O’Neil, Dorothy; Metcalf, Julia A.; King, Karen; Burgess, Timothy H.; Aga, Evgenia; Lane, H. Clifford; Hughes, Michael D.; Davey, Richard T.
Title: A Randomized Study of Immune Plasma for the Treatment of Severe Influenza Document date: 2017_5_15
ID: 2g22oqf2_30
Snippet: The use of immune plasma has been recommended as a primary therapy for severe respiratory infectious diseases, including influenza, SARS and MERS. [9] However, data supporting these recommendations are weak and limited to case reports, case series, and one case control study. [10] Additionally, a randomized controlled trial of hyper-immune antiinfluenza immunoglobulin did not show any benefit in mortality, ICU stay, or hospital stay. [11] A post-.....
Document: The use of immune plasma has been recommended as a primary therapy for severe respiratory infectious diseases, including influenza, SARS and MERS. [9] However, data supporting these recommendations are weak and limited to case reports, case series, and one case control study. [10] Additionally, a randomized controlled trial of hyper-immune antiinfluenza immunoglobulin did not show any benefit in mortality, ICU stay, or hospital stay. [11] A post-hoc analysis of participants treated within 5 days of symptom onset was reported as demonstrating reduced mortality (0/12 (0%) vs 4/10 (40%), OR, 0.14; p =0.04), though conversely those treated after 5 days had an increased mortality (5/5 (100%) vs 0/7 (0%), no statistical analysis reported).
Search related documents:
Co phrase search for related documents- case control and hospital stay: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- case control and hospital stay ICU stay: 1, 2
- case control and ICU stay: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- case control and increase mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- case control and infectious disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- case control and mortality benefit: 1, 2
- case control and post hoc analysis: 1
- case control and primary therapy: 1, 2, 3
- case control and recommendation support: 1, 2
- case control and reduce mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- case control study and control trial: 1, 2, 3, 4, 5, 6, 7
- case control study and hospital stay: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- case control study and ICU stay: 1, 2, 3, 4, 5, 6, 7, 8, 9
- case control study and increase mortality: 1, 2, 3, 4, 5, 6, 7
- case control study and infectious disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- case control study and mortality benefit: 1
- case control study and primary therapy: 1, 2, 3
- case control study and recommendation support: 1
- case control study and reduce mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
Co phrase search for related documents, hyperlinks ordered by date